FDA Patient-Focused Drug Development Meeting on Nonhealing Chronic Wounds
On August 25, 2026, the U.S. Food and Drug Administration (FDA) is hosting a hybrid public meeting on Patient-Focused Drug Development for Nonhealing Chronic Wounds. This meeting will provide FDA and other key stakeholders, including medical product developers, health care providers, and academic researchers, the opportunity to hear directly from patients, patient representatives, and care partners about their experiences with nonhealing chronic wounds, including how the wounds and associated wound care affect their daily life, what matters most to them, their current approaches for managing or treating their nonhealing chronic wounds, and what they consider when determining whether to participate in a clinical trial.
There will be three sessions focused on: (1) health effects and daily impacts, (2) current approaches to treatment, and (3) perspectives on clinical trials. For each topic, a brief initial patient panel discussion will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other patient and care partner participants in the audience. Panelists are also welcome to participate in the facilitated discussion.
This webpage will be updated as meeting materials are developed.
Panelists
Panelists are composed of patients or their care partners. This is a patient-centric initiative. If you know anyone receiving wound care who may be interested in participating in this discussion, it will be live in Maryland and virtual. There is a registration process that is due July 3, 2026.
Date: August 25, 2026
Time: 10:00 AM – 4:30 PM ET
Location: Attend In Person or Online
Virtual: Via webcast
In Person: FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503
Silver Spring, MD 20993
United States
Register Now
There is also an opportunity for individuals who have experienced the need for wound care to submit written comments via email.
Public Docket
Individuals who have received or are receiving wound care are also encouraged to submit written comments to the public docket by October 26, 2026, or visit www.regulations.gov and search for FDA-2026-N-5057.
